Sugi Predict

Sugi Predict / Targets / KMT5A

KMT5A

N-lysine methyltransferase KMT5A · Q9NQR1 · KMT5A on Sugi Atlas →

2,415 patent compounds predicted against KMT5A, 1,515 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL3980630 SCHEMBL3980630 0.50 16/20
SCHEMBL11851777 SCHEMBL11851777 0.46 16/20
SCHEMBL17122656 SCHEMBL17122656 0.58 15/20
SCHEMBL17122659 SCHEMBL17122659 0.56 15/20
SCHEMBL11852328 SCHEMBL11852328 0.54 15/20
Nitric Acid Nitric Acid (SCHEMBL11851757) 0.48 15/20
SCHEMBL3640926 SCHEMBL3640926 0.65 14/20
SCHEMBL14375430 SCHEMBL14375430 0.56 14/20
SCHEMBL7236460 SCHEMBL7236460 0.55 14/20
SCHEMBL5049937 SCHEMBL5049937 0.66 13/20
SCHEMBL7259546 SCHEMBL7259546 0.59 13/20
SCHEMBL7259303 SCHEMBL7259303 0.55 13/20
SCHEMBL17122603 SCHEMBL17122603 0.51 13/20
SCHEMBL9690146 SCHEMBL9690146 0.44 13/20
SCHEMBL5049818 SCHEMBL5049818 0.71 12/20
SCHEMBL3972349 SCHEMBL3972349 0.60 12/20
SCHEMBL3975061 SCHEMBL3975061 0.47 12/20
SCHEMBL18095981 SCHEMBL18095981 0.47 12/20
SCHEMBL17122658 SCHEMBL17122658 0.47 12/20
SCHEMBL1291780 SCHEMBL1291780 0.64 11/20

Clinical trials — most relevant to KMT5A by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Phase 1/ Phase 2 Study to Assess Safety and Efficacy of Orally Administered JBI-802 in Subjects With Myeloproliferative Neoplasms (MPN) and Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN) With Thrombocytosis PHASE1/PHASE2RECRUITING
Safety and Efficacy of BMS-986504 in Unresectable Malignant Peripheral Nerve Sheath Tumor PHASE1/PHASE2NOT_YET_RECRUITING
A Study of PRMT5 Inhibitor BAY 3713372 in Participants With MTAP-deleted Solid Tumors PHASE1/PHASE2RECRUITING
Treatment With Azacitidine of Recurrent Gliomas With IDH1/2 Mutation PHASE2UNKNOWN
IDH1 (AG 120) Inhibitor in Patients With IDH1 Mutated Myelodysplastic Syndrome PHASE2ACTIVE_NOT_RECRUITING
New Treatment Strategies and Epigenetic Biomarker for Management of Benign Prostatic Hyperplasia PHASE2RECRUITING
IDH2 (AG 221) Inhibitor in Patients With IDH2 Mutated Myelodysplastic Syndrome PHASE2ACTIVE_NOT_RECRUITING
A Study of JNJ-75276617 in Combination With Conventional Chemotherapy for Pediatric and Young Adult Participants With Relapsed/Refractory Acute Leukemias PHASE1WITHDRAWN
Phase I Trial of 4'-Thio-2'-Deoxycytidine (TdCyd) in Patients With Advanced Solid Tumors PHASE1COMPLETED
5-aza-4'-Thio-2'-Deoxycytidine (Aza-TdC) in People With Advanced Solid Tumors PHASE1RECRUITING
Safety, Tolerability and Pharmacokinetics of Benfo-Oxythiamine (B-OT) in Healthy Volunteers PHASE1COMPLETED
Phase I Dose Finding and Proof-of-concept Study of Panobinostat With Standard Dose Cytarabine and Daunorubicin for Untreated Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome PHASE1COMPLETED
Studying The Role of Key Epigenetic Mediators in Breast Cancer Patients nanRECRUITING
PHF19 Gene Expression and EZH2 Gene Deletion in Acute Myeloid Leukemia nanUNKNOWN
Exploiting Epigenome Editing in Kabuki Syndrome: a New Route Towards Gene Therapy for Rare Genetic Disorders nanCOMPLETED
Mechanisms of Immune Deficiency nanUNKNOWN
Target of Suv420h1/2 in Hepatocytes nanRECRUITING
The Crosstalk Between the Epigenome and Mitochondria in SCI nanNOT_YET_RECRUITING
The Molecular Pathogenesis Study of Cataract nanUNKNOWN
A Study of Multilocus Methylation Abnormalities in Subjects With Imprinting Disorders nanNOT_YET_RECRUITING
The Danish TURNER Cryopreservation Study nanRECRUITING
Diagnosis of RSTS: Identification of the Acetylation Profiles as Epigenetic Markers for Assessing Causality of CREBBP and EP300 Variants. nanUNKNOWN
MYT1L Syndrome: a Rare Paediatric Genetic Syndrome Responsible for a Neurodevelopmental Disorder nanRECRUITING
Clinical, Radiological, Histologic and Molecular Features of a Cohort of Melanocytic Tumors of the Central Nervous System nanUNKNOWN
Study of Tazemetostat in Adults With Follicular Lymphoma Previously Treated With at Least Two Therapies nanWITHDRAWN
Impact of a Monoamine Oxidase Inhibitor on the Phenotype of Blood Mononucleated Cells in Patients With COVID-19 nanCOMPLETED
Long-read Genome Sequencing for the Molecular Diagnosis of Dystonia nanRECRUITING
A Study of the Interaction Between Tumor Susceptibility Gene Glycine N-methyltransferase (GNMT) and Lung Cancer nanUNKNOWN
The Association of G9a Protein and Clinical Outcome of Patients With Vulvar Cancer nanUNKNOWN
Epigenetic Evaluation of HAT/HDAC Activity in PBMC From Patients With Clinically Isolated Syndrome nanUNKNOWN

Related proteins — ESM-2 sequence neighbours (a KMT5A binder may also engage these)

ProteinNameSimilarity
Q2YDW7 — 0.993 Q2YDW7 →
Q2YDJ8 — 0.993 Q2YDJ8 →
Q071E0 — 0.977 Q071E0 →
Q8WY91 — 0.971 Q8WY91 →
Q0V9E9 — 0.971 Q0V9E9 →
A4FV61 — 0.970 A4FV61 →
Q498E6 — 0.970 Q498E6 →
A0JPQ7 — 0.969 A0JPQ7 →
Q2TBI2 — 0.968 Q2TBI2 →
Q642B6 — 0.967 Q642B6 →
O88974 — 0.967 O88974 →
Q66JB6 — 0.967 Q66JB6 →
Q96ME7 — 0.966 Q96ME7 →
Q08AY6 — 0.966 Q08AY6 →
Q5R6F3 — 0.965 Q5R6F3 →
Q62511 — 0.965 Q62511 →
SETDB1 Histone-lysine N-methyltransferase SETDB1 0.964 landscape →
Q496Y0 — 0.964 Q496Y0 →
Q9NQV5 — 0.964 Q9NQV5 →
Q96N64 — 0.964 Q96N64 →
Q62925 — 0.964 Q62925 →
ZFP91 E3 ubiquitin-protein ligase ZFP91 0.963 landscape →
Q92667 — 0.963 Q92667 →
Q02040 — 0.963 Q02040 →
Q80TL0 — 0.962 Q80TL0 →
Q99MU3 — 0.962 Q99MU3 →
Q8WYQ5 — 0.962 Q8WYQ5 →
Q9WU40 — 0.962 Q9WU40 →
Q6P3Z3 — 0.962 Q6P3Z3 →
Q80Z30 — 0.962 Q80Z30 →